Director
Epidemiology & Benefit–Risk Evaluation, Sanofi
Dr. Jian-Yu E is the Director of Pharmacoepidemiology at Sanofi over 10 years of expertise spanning clinical medicine, pharmacovigilance, and biostatistics. With a focus on pharmaceutical industries, he adeptly designs and implements cutting-edge pre- and post-approval epidemiology analyses, real-world evidence, and outcome modeling solutions. Dr. E's extensive experience with regulatory interactions, coupled with unwavering commitment to upholding compliance standards, underscores his ability to navigate complex regulatory landscapes. Dr. E's leadership shines through his strategic contributions to decision-making processes, integrating clinical insights into diverse areas such as PASS/PMR, clinical trials, real-world evidence, and Health Economics and Outcome Research (HEOR). His extensive research portfolio encompasses a wide range of therapeutic areas, including neurology, oncology, hematology, ophthalmology, gerontology, endocrinology, and rare diseases. Notably, he has provided invaluable data-driven guidance for drug development pipelines and offered consultative expertise to prominent pharmaceutical companies. Dr. E's methodological versatility is evident in his adept utilization of various data sources, including disease epidemiology and management, treatment patterns, healthcare utilization, comparative effectiveness and safety research, indirect treatment comparisons, systematic reviews, economic modeling, patient-reported outcomes, and preference study. Remarkably, Dr. E has published 35 papers in top-tier journals (13 as first/corresponding author) including JAMA Ophthalmology, JAMA Surgery, Lancet Oncology, Lancet -EClinical Medicine and Ophthalmology, and served as a board member for 3 respected journals for American Journal of Clinical Oncology, Journal of Clinical Trials, International Journal of Clinical Trials.